Cartesian Therapeutics (RNAC) Times Interest Earned (2016 - 2023)
Cartesian Therapeutics (RNAC) has disclosed Times Interest Earned for 8 consecutive years, with -$10.26 as the latest value for Q3 2023.
- On a quarterly basis, Times Interest Earned fell 414.76% to -$10.26 in Q3 2023 year-over-year; TTM through Jun 2024 was -$38.48, a 158.84% decrease, with the full-year FY2023 number at -$30.5, down 735.96% from a year prior.
- Times Interest Earned was -$10.26 for Q3 2023 at Cartesian Therapeutics, up from -$24.78 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $19.38 in Q2 2022 to a low of -$79.84 in Q2 2020.
- A 5-year average of -$19.9 and a median of -$11.08 in 2020 define the central range for Times Interest Earned.
- Peak YoY movement for Times Interest Earned: skyrocketed 2949.22% in 2022, then plummeted 414.76% in 2023.
- Cartesian Therapeutics' Times Interest Earned stood at -$37.52 in 2019, then surged by 70.48% to -$11.08 in 2020, then skyrocketed by 151.78% to $5.74 in 2021, then tumbled by 283.55% to -$10.53 in 2022, then rose by 2.51% to -$10.26 in 2023.
- Per Business Quant, the three most recent readings for RNAC's Times Interest Earned are -$10.26 (Q3 2023), -$24.78 (Q2 2023), and -$22.75 (Q1 2023).